Done Deal: Crown Completes Acquisition of Revance
Crown Laboratories, Inc. and Hildred Capital have acquired Revance Therapeutics, Inc. Crown will buy Revance at $3.65 per share, and Revance will be delisted from NASDAQ following the acquisition. “We are excited to officially welcome Revance to the Crown family,” says Jeff Bedard, Founder and Chief Executive Officer of Crown, in a news release. “This acquisition […]